Background: The 'Shock and Kill' strategy is pivotal in the quest for an HIV/AIDS cure. Our study explores Methods: We conducted a phase 1b/2a clinical trial at the Shanghai Public Health Clinical Center (NCT04503928). People with HIV (PWH) on ART were assigned to three groups: 1 g qd (once per day) for 7 days, 1g bid (twice per day) for 7 days, or 1 g qd for 14 days. Blood was collected on Days 0, 1, 3, 5, 7, 14, and 21. Primary en dpoints included changes from baseline in cell-associated (CA) HIV RNA and plasma HIV viral load, while secondary endpoints involved integrated HIV DNA levels and safety assessments. Results: Nine PWHs male participants (mean age: 38.78 ± 13.85 years old) with a median antiviral treatment duration of 49 months, were enrolled in the clinical study. HIV latency reversal was primarily observed within the first seven days following Kansui administration. A ≥2-fold increase in cell-associated (CA) HIV RNA was detected in four participants, three of whom received the 1 g qd dose. Additionally, two participants exhibited a transient increase in plasma HIV RNA to >50 copies/mL, with one case in the 1 g qd for 7 days group and the other in the 1 g qd for 14 days group. Integrated HIV DNA levels transiently increased during the intervention and then quickly returned to baseline levels without significant decline. Kansui demonstrated a favorable safety profile, with no serious adverse events reported and only mild adverse events observed. Conclusion: Kansui can reactivate latent HIV viral reservoirs at a low-level in vivo and is well tolerated by PWHs on antiretroviral therapy which warrant further investigation.